About 26 results found for searched term "LM10" (0.121 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M10116 | LM10 | IDO |
| LM-10 | ||
| LM10 is a selective tryptophan 2,3-dioxygenase (TDO) inhibitor (IC50 values are 0.62 and 2 μM for human and mouse TDO, respectively). | ||
| M11011 | LM22B-10 | Trk |
| LM22B-10 is a TrkB/TrkC neurotrophic factor receptor activator that induces activation of TrkB, TrkC, AKT and ERK in vitro. | ||
| M50158 | LM-108 | CCR |
| LM-108 is a novel anti-CCR8 monoclonal antibody that efficiently eliminates tumor-associated Tregs in a mouse model through antibody-dependent cell-mediated cytotoxicity (ADCC) without affecting peripheral Tregs, showing potent anti-tumor activity, and can be used for tumor-related studies. | ||
| M51168 | Palmitoyl tetrapeptide-10 | Others |
| Palmitoyl tetrapeptide-10isa bioactive peptide with anti-aging effect and has been reported used as a cosmetic ingredient. | ||
| M8622 | TVB-3166 | FAS |
| TVB3166 | ||
| TVB-3166 is a cell-permeable pyrrazole derivative that inhibits cellular palmitate synthesis (IC50 <100 nM) by fatty acid synthase (FASN) keto-reductase activity in a potent and reversible manner (IC50 = 42 nM), effectively inhibiting palmitate-dependent survival of various cancer cells in cultures and xenografted tumor growth in mice vivo (60-100 mg/kg/d p. | ||
| M10645 | MS402 | Epigenetic Reader Domain |
| MS-402 | ||
| MS402 is a novel BD1-selective BET BrD inhibitor, inhibiting primarily Th17 cell differentiation with a little or almost no effect on Th1 or Th2 and Treg cells. MS402 has Ki values of 77 nM, 718 nM, 110 nM, 200 nM, 83 nM, and 240 nM for BRD4(BD1), BRD4(BD2), BRD3(BD1), BRD3(BD2), BRD2(BD1) and BRD2(BD2), respectively. | ||
| M14135 | Almonertinib | EGFR/HER2 |
| HS-10296 | ||
| Almonertinib (HS-10296) is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. | ||
| M14136 | Almonertinib hydrochloride | EGFR/HER2 |
| HS-10296 hydrochloride | ||
| Almonertinib (HS-10296) hydrochloride is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. | ||
| M21087 | VT103 | YAP |
| VT103, a VT101 analog, is a selective and orally active TEAD1 protein palmitoylation inhibitor that can be used in cancer research. VT103 inhibits the transcription of YAP/TAZ-TEAD promoted gene, blocks the auto-palmitoylation of TEAD, and interferes with the interaction between YAP/TAZ and TEAD. | ||
| M21500 | Polmacoxib | COX |
| CG100649 | ||
| Polmacoxib (CG100649) is a first-in-class, orally active non-steroidal anti-inflammatory compound (NSAID) that acts as a dual inhibitor. It inhibited COX-2 (IC50 ~ 0.1 μg/ml) and carbonic anhydrase. | ||
| M21662 | MGH-CP1 | Apoptosis |
| MGH-CP1 is a potent and orally active TEAD2 and TEAD4 auto-palmitoylation inhibitor with IC50s of 710 nM and 672 nM, respectively. MGH-CP1 can decrease the palmitoylation levels of endogenous or ectopically expressed TEAD proteins in cells. | ||
| M27835 | Bisindolylmaleimide V | S6 Kinase |
| BIM V | ||
| Bisindolylmaleimide V is a cell-permeable negative control for protein kinase C inhibition studies with an IC50 value over 100 µM. Bisindolylmaleimide V blocks the activation of mitogen-stimulated protein kinase p70s6k/p85s6k (S6K) in vivo with an IC50 of 8 µM. | ||
| M28191 | PF 1022A | Parasite |
| PF 1022A is a cyclooctadepsipeptide with broadspectrum anthelmintic properties produced by fermentation of the fungus Mycelia sterilia. PF 1022A is a channel-forming ionophore. PF 1022A showes strong anthelmintic activities against Ascaridia galli in chickens. PF 1022A also can be used for angiostrongyliasis research. | ||
| M28522 | Levamisole | AChR/AChE |
| (-)-Tetramisole | ||
| Levamisole ((-)-Levamisole), an anthelmintic agent with immunomodulatory properties. Levamisole acts as a positive allosteric modulator (PAM) for the α3β2 (EC50=300 μM) and α3β4 (EC50=100 μM) subtype of nAChRs. Orally active. | ||
| M28945 | Gilmelisib | PI3K |
| Gilmelisib is an antineoplastic. Gilmelisib is a PI3K inhibitor (IC50 <1 nM for PI3K p110α). | ||
| M29628 | VT104 | YAP |
| VT104 is a potent and orally active YAP/TAZ inhibitor. VT104 prevents palmitoylation of endogenous TEAD1 and TEAD3 proteins. VT104 can be used in research of cancer. | ||
| M29974 | 10,11-Dihydrocarbamazepine | Metabolite/Endogenous Metabolite |
| 10,11-Dihydrocarbamazepine is the active metabolite of Oxcarbazepine. 10,11-Dihydrocarbamazepine also is an intermediate. Oxcarbazepine is rapidly and almost completely converted to 10,11-Dihydrocarbamazepine with probable Anticonvulsant efficacy. | ||
| M30049 | AMA-37 | DNA-PK |
| AMA-37, an Arylmorpholine analog, is ATP-competitive DNA-PK inhibitor, with IC50 values of 0.27 μM (DNA-PK), 32 μM (p110α), 3.7 μM (p110β), and 22 μM (p110γ), respectively. | ||
| M30192 | Org 43553 | Others |
| Org 43553 is an orally active and low molecular weight (LMW) luteinizing hormone receptor (LH-R) agonist. Org 43553 shows agonistic activity to human LH and FSH receptors with EC50 values of 3.7 and 110 nM, respectively. Org 43553 can be used for the research of endocrine. | ||
| M30509 | Rachelmycin | Antibiotic |
| CC-1065; NSC 298223 | ||
| Rachelmycin (CC-1065) is an antitumor antibiotic and a DNA-alkylating agent. Rachelmycin has cytotoxic potency that can be used as a cytotoxin to synthesis ADC. Rachelmycin effectively inhibits DNA synthesis. Rachelmycin can be used for cancer and infection research. | ||
| M30583 | 8-OH-DPAT hydrobromide | 5-HT Receptor |
| 8-Hydroxy-DPAT hydrobromide | ||
| 8-OH-DPAT (8-Hydroxy-DPAT) hydrobromide is a potent and selective 5-HT1A agonist with a pIC50 of 8.19. 8-OH-DPAT hydrobromide has selectivity of almost 1000 fold for a subtype of the 5-HT1 binding site. | ||
| M30952 | Lck inhibitor 2 | Src-bcr-Abl |
| Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively IC50 Value: 13 nM(Lck) [1] Target: Src family kinase Lck inhibitor 2(Compound 9) inhibited 48 kinases with %control < 1 (33 of them tyrosine kinases, almost half of the 71 tyrosine kinases in the panel). A further 27 kinases were bound with %control < 10. Kd values for 16 kinases were determined and found to be below 100 nM. These included TXK (10 nM). | ||
| M49947 | Ifabotuzumab | Ephrin Receptor |
| KB004 | ||
| Ifabotuzumab is an IgG1κ antibody (KD=610 pM) targeting EphA3. Ifabotuzumab is able to cause apoptosis of tumor cells and activate antibody-dependent cell-mediated cytotoxicity (ADCC), which disrupts the tumor vascular system. In addition, Ifabotuzumab reduces idiopathic pulmonary fibrosis (IPF) CCR10+ cells and ameliorates pulmonary fibrosis. | ||
| M54029 | Calcineurin autoinhibitory peptide | Phosphatase |
| Calcineurin autoinhibitory peptide is a selective inhibitor of Ca2+/calmodulin-dependent protein phosphatase (calcineurin), with an IC50 of ~10 μM. | ||
| M54145 | Beinaglutide | Glucagon Receptor |
| Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). | ||
| M54779 | Pralmorelin | Others |
| GHRP-2 | ||
| Pralmorelin (also known as KP-102, GPA-748, GHRP-2, and Growth Hormone Releasing Peptide-2) is a potent growth hormone secretagogue that acts on the pituitary gland and the hypothalamus to stimulate and amplify pulsatile growth hormone release. It acts as signal molecules that are involved in the control of cell growth and differentiation. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
